Allurion Technologies, Inc. announced its preliminary unaudited results for the fourth quarter and full year 2025, revealing significant growth and operational improvements.
The company reported strong quarter-over-quarter revenue growth and a notable decrease in operating expenses and losses, indicating a positive trajectory for future efficiency.
Management forecasts a 22% to 37% increase in fourth-quarter revenue, estimated at $3.3 million to $3.7 million, with full-year revenue expected to reach approximately $15 million.
Revenue Growth
Allurion anticipates a 22% to 37% increase in fourth-quarter revenue to $3.3 million to $3.7 million, reflecting the success of its commercial strategy in driving growth.
- Dr. Shantanu Gaur, Founder and CEO, expressed contentment with the fourth-quarter results, highlighting the positive revenue growth and operational enhancements achieved.
- The impending FDA approval for the Allurion Smart Capsule in 2026 is poised to be a pivotal milestone, augmenting Allurion's standing in metabolically healthy weight loss solutions.
Allurion Technologies is primed for a transformative year in 2026, buoyed by robust revenue growth, cost efficiencies, and strategic advancements in weight loss solutions. The upcoming FDA approval of the Allurion Smart Capsule further underscores the company's innovation and growth potential.